The Haddad Group at Morgan Stanley.
Al Haddad, Wealth Advisor
Kristin Jones, Wealth Management Associate.
For more info, please visit our website!
NMLS#1285425
Great first day. 53 attended with fantastic effort and persistence. Great job ladies. 40 boxes of pancakes and syrup for the Pantry made the day complete. Thank you. See you Wednesday.
Although many investors view markets as a highly efficient prognostic machine, the surprises of the 2016 election may have created more hesitancy to guess election outcomes.
https://t.co/CO6YyxbcQ1
Although it’s possible that the results of the 2020 U.S. election won’t come on Nov. 3rd, there is some fresh evidence that it may unfold more smoothly than pundits predict.
https://t.co/e3p9jirKWc
MS & Co. CIO Mike Wilson notes that although the bull market appears intact, investor sentiment has remained remarkably skeptical. Learn more: https://t.co/2QPg1EoriL
Do tech-driven energy efficiencies—coupled with a shift in environmental attitudes—mean oil demand will fail to recover to pre-COVID levels? https://t.co/2JvCw03mpW
With mixed signals coming from the White House and Congress, should investors be concerned about no further stimulus? Why there may still be good news. https://t.co/x7Vg8LjRrP
Trading corrections is difficult so the best approach may be to ride it out, says Morgan Stanley & Co. CIO Mike Wilson. Read more: https://t.co/MuT5aUxqSO
Stocks rally while long-end rates test four-month highs as markets react to the latest updates in Washington. Read more in the 1% Move report: https://t.co/KDz8A4n9uN
With a U.S. fiscal stimulus deal looking more likely, the risk of long-term interest rates moving higher has now increased—a shift that could benefit recovery stocks. https://t.co/KNmbIOKrCG
While stocks have grown more volatile as the election approaches, interest rates have barely budged. That may not last once the election outcome is clear. Here’s why: https://t.co/ganoLVmO7j
For markets, a vaccine may be the most significant sign the world may return to a more normal future. But what are markets pricing in currently?
https://t.co/5TA26ObUNe
COVID-19 vaccines are navigating through the last stage of clinical trials, but hurdles still lie ahead for efficacy, distribution and FDA approval.
https://t.co/mgXkCTsTGs
How will markets react if final U.S. election results take days or weeks? Head of U.S. Public Policy Research Michael Zezas shares advice for investors.
https://t.co/FHCO2Exph2
The recent correction may have been inevitable given rising risks for fiscal stimulus, a potential COVID-19 second wave and the upcoming election. But a resolution to these hurdles may also be possible longer-term.
https://t.co/8XpTZg8f1d